NDLI: Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study

Content Provider	Springer Nature : BioMed Central
Author	Faverio, Paola Ronco, Raffaella Monzio Compagnoni, Matteo Franchi, Matteo Franco, Giovanni Bonaiti, Giulia Bonifazi, Martina Mei, Federico Luppi, Fabrizio Pesci, Alberto Corrao, Giovanni
Abstract	Rationale Severe asthma is burdened by relevant socio-economic and clinical impact. Randomized controlled trials on Dupilumab showed efficacy and a good safety profile, but post-market studies are needed. Objectives To evaluate the impact of Dupilumab on (i) the use of anti-asthmatic drugs, including oral corticosteroids (OCS), (ii) the rates of asthma exacerbation-related hospital admissions, and (iii) the healthcare costs in patients with asthma. Methods Data were retrieved from Healthcare Utilization database of Lombardy region (Italy). We compared healthcare resources use between the 6 months after Dupilumab initiation (“post-intervention period”) and (i) the 6 months before Dupilumab initiation (“wash-out period”) and (ii) the corresponding 6 months of the prior year (“pre-intervention period”). Main results In a cohort of 176 patients, Dupilumab significantly reduced anti-asthmatic drugs use (including OCS and short-acting β2-agonists, inhaled corticosteroids (ICS)/long-acting β2-agonists and ICS alone) when comparing the “pre-intervention” to the “post-intervention” period. When considering hospital admissions, we observed a not statistically or marginally significant reduction between both periods before Dupilumab and the post-intervention period. Six-months discontinuation rate was 8%. Overall healthcare costs had a tenfold increase between the “pre-intervention” and “post-intervention” period, which was mainly led by the biologic drug cost. Conversely, expenditures connected to hospital admissions did not change. Conclusions Our real-world investigation suggests that Dupilumab reduced anti-asthmatic drugs use, including OCS, in comparison to a corresponding period in the prior year. However, long-term healthcare sustainability remains an open issue.
Related Links	https://respiratory-research.biomedcentral.com/counter/pdf/10.1186/s12931-023-02372-y.pdf
Ending Page	9
Page Count	9
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s12931-023-02372-y
Journal	Respiratory Research
Issue Number	1
Volume Number	24
Language	English
Publisher	BioMed Central
Publisher Date	2023-03-07
Access Restriction	Open
Subject Keyword	Pneumology Respiratory System Asthma Clinical allergy and immunology Inflammation Pneumology/Respiratory System
Content Type	Text
Resource Type	Article
Subject	Pulmonary and Respiratory Medicine
Journal Impact Factor	4.7/2023
5-Year Journal Impact Factor	5.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Treatment of idiopathic anaphylaxis with dupilumab: a case report

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Association between depression and mortality in persons with asthma: a population-based cohort study

Facial erythema after the treatment of dupilumab in SLE patient

Effective use of dupilumab for eosinophilic gastritis concomitant with severe asthma

Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

Shared prenatal impacts among childhood asthma, allergic rhinitis and atopic dermatitis: a population-based study

Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study

Similar Documents

Treatment of idiopathic anaphylaxis with dupilumab: a case report

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Association between depression and mortality in persons with asthma: a population-based cohort study

Facial erythema after the treatment of dupilumab in SLE patient

Effective use of dupilumab for eosinophilic gastritis concomitant with severe asthma

Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

Shared prenatal impacts among childhood asthma, allergic rhinitis and atopic dermatitis: a population-based study

Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study